← FDA DRUG APPROVALS
FDA ANDA · ANDA210160
ALOGLIPTIN; METFORMIN HYDROCHLORIDE
Sponsor: TORRENT PHARMS LTD
APPLICATION
ANDA210160
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
ALOGLIPTIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
ALOGLIPTIN EQ 12.5MG BASE, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
ALOGLIPTIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
ALOGLIPTIN EQ 12.5MG BASE, METFORMIN HYDROCHLORIDE 1GM · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.